MoonLake Immunotherapeuti... (MLTX)
38.93
-0.38 (-0.97%)
At close: Mar 13, 2025, 11:52 AM
MoonLake Immunotherapeutics Balance Sheet Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 |
| Cash & Equivalents | 180.43M | 451.17M | 39.51M | 8.04M | 1.34M |
| Short-Term Investments | 267.6B | 59.84M | 32.61M | n/a | n/a |
| Long-Term Investments | n/a | n/a | n/a | 115.04M | 115.01M |
| Other Long-Term Assets | 3.64B | 8.42M | -0.00 | -115.04M | n/a |
| Receivables | 2.84M | 1.06M | 217.13K | 148.77K | n/a |
| Inventory | n/a | n/a | n/a | 1.32M | n/a |
| Other Current Assets | 23.42B | 2.1M | 4.18M | 1.45M | 283.06K |
| Total Current Assets | 474.29B | 514.17M | 76.51M | 9.64M | 1.62M |
| Property-Plant & Equipment | 3.64M | 3.95M | 331.97K | 45.74K | n/a |
| Goodwill & Intangibles | n/a | n/a | n/a | n/a | n/a |
| Total Long-Term Assets | 3.64B | 12.37M | 331.97K | 45.74K | 115.01M |
| Total Assets | 477.93B | 526.54M | 76.84M | 9.68M | 116.63M |
| Account Payables | 8.68M | n/a | 47.48K | 1.23M | n/a |
| Deferred Revenue | n/a | n/a | n/a | n/a | n/a |
| Short-Term Debt | 1.37M | 1.31M | 153.63K | 15M | 58.06K |
| Other Current Liabilities | 22.45B | 8.29M | 7.35M | 4.79M | 67.12K |
| Total Current Liabilities | 22.46B | 9.97M | 7.67M | 21.09M | 125.18K |
| Long-Term Debt | 1.46M | 2.5M | 128.95K | n/a | n/a |
| Other Long-Term Liabilities | 2.08B | 583.42K | 282.21K | 239.86K | 4.03M |
| Total Long-Term Liabilities | 2.08B | 3.08M | 411.16K | 239.86K | 4.03M |
| Total Liabilities | 24.54B | 13.05M | 8.08M | 21.33M | 4.15M |
| Total Debt | 2.83M | 3.81M | 282.58K | 15M | 58.06K |
| Common Stock | 6.39K | 6.3K | 5.27K | 38.54K | 115M |
| Retained Earnings | -235.59B | -116.66M | -80.65M | -53.64M | -2.52M |
| Comprehensive Income | 5M | 2.36M | 350.95K | -168.18K | n/a |
| Shareholders Equity | 446.83B | 495.68M | 48.9M | -11.65M | 112.48M |
| Total Investments | 267.6B | 59.84M | 32.61M | 115.04M | 115.01M |